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Pregnancy and Graves’ Disease
Anca Maria Panaitescu
Abstract
Graves’ disease (GD) is one of the most common autoimmune conditions 
in women of reproductive age. The disorder is characterized by the presence of 
pathogenic immunoglobulins that bind the TSH receptors (TRAbs) and stimulate 
the production of thyroid hormones leading to hyperthyroidism (the occurrence of 
inhibiting or neutral antibodies being rare). Affected individuals can be treated by 
radioiodine therapy, surgical removal of the gland or by antithyroid drugs (ATDs). 
Thyroid stimulating immunoglobulins may persist for years after medical treat-
ment, radioiodine therapy or surgical removal of the gland in those affected by GD 
and during pregnancy can cross the placenta and can act on the fetal thyroid gland 
resulting in the development of fetal and neonatal hyperthyroidism and sometimes 
to goiter. Antithyroid drugs used during pregnancy can also cross the placenta and 
may be teratogenic and act on the fetal thyroid gland, leading to fetal and neonatal 
hypothyroidism and goiter. This chapter will discuss specific aspects of GD during 
pregnancy and postpartum focusing on fetal and neonatal consequences related to 
this disorder.
Keywords: pregnancy, Graves’ disease, TRAb, anti-thyroid drugs, fetal goiter,  
fetal hypothyroidism, fetal hyperthyroidism
1. Introduction
Graves’ disease (GD) is one of the most common autoimmune conditions in 
women of reproductive age. Pathogenic immunoglobulins that bind the TSH 
receptors (TRAbs) are the hallmark of GD and stimulate the production of thyroid 
hormones leading to hyperthyroidism (the occurrence of inhibiting or neutral anti-
bodies being exceptional). Treatment for affected individuals is either by radioio-
dine therapy, surgical removal of the gland or by antithyroid drugs (ATDs). TRAbs 
may persist for years after medical treatment, radioiodine therapy or surgical 
removal of the gland in those affected by Graves’ disease and during pregnancy can 
cross the placenta by hijacking the physiological maternal-fetal antibody transfer 
pathways [1] and can act on the fetal thyroid gland resulting in the development of 
fetal hyperthyroidism and sometimes to fetal goiter. Antithyroid drugs used during 
pregnancy can also cross the placenta and may be teratogenic and act on the fetal 
thyroid gland, leading to hypothyroidism and fetal goiter.
The maternal thyroid gland undergoes extensive changes during pregnancy and 
postpartum. These changes are supported by the interaction between the fetal-
placental unit and the maternal endocrine system and are reflected in the thyroid 
function tests, which differ from outside pregnancy as early as first trimester. 
Normal fetal development depends on maternally derived thyroid hormones (TH) 
at least until 16–18 weeks’ gestation when the fetal thyroid starts to function [2].
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This chapter will discuss specific aspects of Graves’ disease during pregnancy 
and postpartum with focus on its fetal and neonatal consequences.
2.  Physiological changes of the thyroid gland and the thyroid hormone 
metabolism during pregnancy
The maternal thyroid gland and thyroid hormone metabolism undergo signifi-
cant changes in pregnancy. The volume of the gland and its blood supply increase 
in pregnancy [3]. Plasma volume expands thus increasing total T4 and T3 pool size 
(T4 - thyroxine and T3 - tri-iodothyronine). The placenta produces estrogen that 
induces hepatic synthesis of thyroid-binding globulin (TBG), the main protein 
involved in serum transport of TH, thus increasing levels of total T4 (TT4) and T3 
(TT3) in the maternal plasma. Thyroid hormone production is dependent of iodine 
supply so iodine metabolism needs to keep up with these changes, hence, there is an 
increase in iodine requirements during pregnancy to both meet the maternal and 
fetal demands and to overcome the increased clearance by the kidneys. The placenta 
also produces HCG (human chorionic gonadotropin), a glycoprotein hormone 
with molecular similarity of its α-subunit with TSH (thyroid stimulating hormone) 
which acts as an agonist of TSH raising transiently free T4 levels and decreasing 
serum TSH levels. These changes are more relevant to the first trimester, and, 
beyond it, maternal thyroid hormone levels gradually return to those seen in the 
nonpregnant state [4].
Thyroid hormones are essential for normal development of the fetus and par-
ticularly of the fetal brain. The fetal thyroid gland only starts to produce adequate 
amounts of thyroid hormones in the second trimester; the first trimester fetus relies 
on maternal delivery of thyroid hormones to develop [2]. In the first part of preg-
nancy, before the fetal thyroid starts to work, T4 can be detected in fetal blood and 
brain, indicating that there is relevant transfer of maternal thyroid hormones to the 
fetus. The way maternal thyroid hormones are transferred across the placenta and 
in the fetal brain is not completely understood. Even though thyroid hormones are 
lipophilic, they can not passively cross the placenta nor the fetal blood–brain barrier 
because they are charged and thus can not cross a phospholipid bilayer [5]. Passage 
across the placenta and into the fetal brain is thought to be dependent on the func-
tion of several mechanisms [6] including: the existence of a specific transportation 
system, the function and expression of iodothyronine deiodinases (D) (enzymes 
that TH) in the placenta and fetal brain, and proteins within trophoblast and fetal 
brain which specifically bind TH. At the level of the placenta specific transporters 
capable of transporting maternal TH like monocarboxylate transporters MCT8 and 
MCT10 have been identified [6, 7]. Deiodinases found in the placenta in high con-
centration are D3, the main inactivating enzyme that catalyze monodiodination of 
T4 to reverse T3 and of T3 to T2, but also, D2, which the primary activating enzyme 
in tissues and locally catalyzes the monodeiodination of T4 to T3 [8]. The iodine 
released by this process might be used as a substrate by the fetus for the synthesis 
of its own thyroid hormones. D2 has been identified in the fetal brain [9] convert-
ing T4 to active T3, thus making it readily available. In the serum, TH are bound to 
liver-synthetized transportation proteins mainly TBG but also albumin and trans-
thyretin. Transthyretin has been identified in the placenta and fetal choroid plex-
uses and is thought to play a role in transporting TH into the cells [10]. TSH does not 
cross the placenta and TSH in the fetal blood remains relatively constant throughout 
pregnancy between 4–8 mU/L [11]. The coordination and interplay between these 
systems ensures adequate availability of maternal TH to the fetus in a critical period 
of development (Figure 1).
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3. Thyroid function tests in pregnancy
The physiological changes occurring in the thyroid gland from the beginning of 
pregnancy reflect in changes of the thyroid function tests. International guidelines 
recommend that ideally, for each population, there should be available trimester 
specific normal ranges for TSH and maternal TH [4]. These data should be derived 
from studies in healthy pregnant women with no known thyroid disease, with no 
evidence of thyroid autoimmunity and with an adequate amount of iodine intake 
for each trimester of pregnancy. In the absence of such data, which in many clini-
cal settings can be difficult to obtain, in order to determine normal first-trimester 
reference ranges for TSH it has been suggested that the lower limit of its reference 
interval used in the non-pregnant state can be reduced by 0.4 mU/L and the upper 
limit by 0.5 mU/L [4]. For a healthy young pregnant woman the upper limit of TSH 
would therefore correspond to a value of 4.0 mU/L in the first trimester. This down-
shifting of the normal TSH reference interval only applies to the first trimester 
values, between 7 and 12 weeks of pregnancy since in the second and third trimes-
ters, TSH levels recover and intervals valid outside pregnancy could be used.
The second most common test used to investigate thyroid function outside as 
well as in pregnancy is free T4 (FT4). FT4 represents the thyroxin that is not bound 
to plasmatic proteins; it constitutes less then 0.1% of total T4 (TT4) but is the active 
form that is up taken by cells. Precise measurement of FT4 is difficult in pregnancy 
in part because of the limitation of the widely used commercial immunoassays to 
account for thyroid hormone concentration changes that occur under the influ-
ence of increased levels of TBG, nonesteryfied fatty acids and decreased albumin. 
Figure 1. 
The interaction between the fetal-placental unit and the maternal endocrine system during pregnancy. TRH – 
Thyrotropin releasing hormone; TSH – Thyroid stimulating hormone; T3 - tri-iodothyronine; T4 – Thyroxine; 
HCG - human chorionic gonadotrophin; TBG - thyroid hormone binding globulin; D3 - type 3 iodothyronine 
deiodinase; D2 - type 2 iodothyronine deiodinase; rT3 – Reverse T3.
Graves’ Disease
4
Therefore, it has been suggested that TT4 and the index of T4 are more accurate in 
determining shifts in thyroid hormone levels in pregnancy. With TT4 it is important 
to acknowledge that its level increases by 50% during weeks 7 to 16 and remain 
high thereafter throughout pregnancy. When the level of TT4 is determined before 
16 weeks, an adjustment to the upper limit of the non-pregnancy interval by 5% 
per week between weeks 7 to 16 could be made. A TT4 measurement with reference 
value 1.5 times the non-pregnancy range may be used in second and third trimesters 
as discussed above. When trimester-specific FT4 values are not available, use of the 
reference range for non-pregnant patients is recommended [4, 12–14].
4. Graves’ disease in pregnancy
4.1 Incidence and pathophysiology
Graves’ disease is one of the most common causes of thyrotoxicosis in women of 
reproductive age. It has been reported in as much as 1 in 500 pregnancies [15] but 
is more frequent in the years prior and after conception. GD presents clinically in 
pregnancy as outside pregnancy with hyperthyroidism, goiter, ophthalmopathy. 
The condition is autoimmune and is characterized by the presence of abnormal 
autoantibodies (TRAbs) directed against the TSH receptor in the thyroid gland. 
These antibodies, unlike anti-thyroperoxidase and anti-tyroglobulin antibodies, 
do have a pathogenic role in the thyroid-related and extra-thyroidal manifestation 
of GD and in pregnancy can cross the placenta and act on the fetal thyroid gland 
[16]. TRAbs are the pathogenic hallmark of GD and are measurable in around 95% 
of patients with active Graves’ hyperthyroidism but can also be found, sometimes 
in high levels, in patients with a history of treated GD [17]. TRAbs are usually of 
the stimulating type, but blocking or neutral autoantibodies have been described 
[18]. TRAbs can cross the placenta by hijacking normal physiological mechanisms 
of antibody transfer that become functional after 16 weeks of pregnancy and can 
get into the fetal blood and act on the fetal TSH receptor, therefore they also have a 
pathogenic role in the fetal consequences of maternal GD, especially when in high 
titers (> 2 to 3 times the upper limit of normal [4].
The types of assays used in clinical settings for TRAb determination are relevant 
to pregnancy. There are two major methods to assess TRAbs in maternal blood: 
by using “receptor assays” and the newer “bioassays”. Receptor or TSH Binding 
Inhibitory Immunoglobulin (TBII) assays detect serum autoantibodies that can 
block the binding of THS to an in vitro prepared receptor. They are of three genera-
tions, with the third-generation TRAbs assays reaching very high sensitivity and 
specificity [19]. They do not measure antibodies’ activity and can not distinguish 
between stimulating or blocking TRAbs types, hence they do not predict the pheno-
type of maternal or fetal GD and do not correlate well with the clinical and biochem-
ical severity of the disease in neither mother nor the fetus [20]. The new bioassays 
are functional tests that characterize the biological properties of TRAbs – stimulat-
ing (TSAbs) or blocking (TBAbs). New bioassays are commercially available to 
measure either TSAbs or TBAbs [21–23]. The functional activity of TRAbs relevant 
in pregnancy since, depending on their type, they can cause either hyperthyroidism 
or hypothyroidism in the fetus, for whom we do not readily have access to blood to 
assess fetal thyroid function as for the mother. Moreover, many women with a his-
tory of GD enter pregnancy in a euthyroid state either by taking medication (ATDs) 
or after undergoing surgery/radioiodine therapy, however, TSAbs and TBAbs can 
stay elevated for years after these procedures. As stated by international guideline 
[4]. TRAbs should be determined during pregnancy for the following categories:
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1. Pregnant women with recently diagnosed GD
2. Pregnant women known with GD and treated with ATDs
3. Women with a previous history of GD with past treatment by radioiodine or 
thyroidectomy
4. A previous history of delivering an infant with hyperthyroidism
5. Known history of thyroidectomy for treatment of hyperthyroidism in 
pregnancy
Fetal and neonatal hyperthyroidism has been reported in 1–5% of infants of 
mothers with GD [24]. In a follow-up study of 47 newborns of mothers with TRAbs 
during pregnancy, 9 infants developed hyperthyroidism and 5 required ATD medi-
cation [25]. A maternal TRAb serum concentration approximately 3 times the upper 
limit of normal for the assay in the second and third trimesters predicted neonatal 
hyperthyroidism with 100% sensitivity and 43% specificity [25]. A similar risk cut-
off for TRAb level was also found in other studies [26]. It is therefore recommended 
to take into consideration determining TRAb levels at the initial thyroid function 
assessment during early pregnancy for those with a history of GD and maybe even 
in those that present for the preconceptional visit. TRAbs should definitely be mea-
sured at the first visit in pregnant women with previous GD that underwent radio-
iodine or surgery, in those requiring ATDs and in those that are first diagnosed with 
GD in pregnancy. If maternal TRAb is undetectable or low in early pregnancy, no 
further testing could be proposed. However, for those with elevated levels, repeated 
testing should occur at 18–22 weeks to guide fetal follow-up. If levels are persistently 
high at 18–22 weeks, repeat testing at 30–34 weeks guides neonatal monitoring [4].
4.2 Differential diagnosis
Graves’ disease can rarely first manifest in the first trimester of pregnancy when 
it is important to be distinguished from gestational transient thyrotoxicosis (GTT) 
or in the postpartum when it should not be confused with the thyrotoxicosis phase 
of the postpartum thyroiditis (PPT). Gestational transient thyrotoxicosis is defined 
as hyperthyroidism of new-onset in the first trimester of pregnancy; it is usually 
associated with hyperemesis gravidarum and is mediated by the interaction of high 
level of HCG with the TSH receptor, hence it is expected to be more common with 
multiple gestation, hydatidiform mole and choriocarcinoma, where HCG levels 
are higher, but it can occur in any pregnant woman. In GTT there are no previous 
signs or symptoms of GD and importantly, TRAbs are not detectable. The condi-
tion is self-limiting and improves in the second trimester of pregnancy, therefore 
ATDs, which are known teratogenic, should be avoided. Supportive treatment 
with hydration, antiemetics, electrolyte replacement and occasionally a short-
course of beta-blockers is sufficient [27]. Postpartum thyroiditis is characterized 
by inflammation secondary to autoimmunity (antithyroid peroxidase antibodies 
[TPO], anti-thyroglobulin antibodies) against the thyroid gland that manifests as 
new-onset thyroid dysfunction specifically developing in the first 12 months after 
a pregnancy in a previously euthyroid woman [28]. The condition typically ensues 
with a hyperthyroid state where the reservoir of thyroid hormones stored in the 
gland is released consequent to inflammation, followed by a hypothyroid state. 
The thyrotoxicosis state is more common in the first 6 months after delivery and 
again is different from GD because it lacks the presence of TRAbs and is generally 
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characterized by milder symptoms: palpitations, heat intolerance, fatigue and 
irritability. PPT is encountered in women with known TPO antibodies in the first 
trimester or in those with a personal or familial history of thyroid disease or other 
autoimmune conditions. It tends to recur after each pregnancy and in most cases the 
affected women recover their euthyroid function within 12 months, however, some 
of them may be persistently hypothyroid. PPT has a prevalence of about 5% [29]. 
Complete and partial hydatidiform moles as in gestational trophoblastic disease 
can sometimes present with thyrotoxicosis in pregnancy. This is more rare than 
previously believed. In a recent cohort-study, completed by a systematic review 
and meta-analysis of cases of hydatidiform moles in missed-miscarriages, in 295 
women with a confirmed histological diagnosis of hydatidiform mole in the first 
trimester there were no cases of thyrotoxicosis [30]. However, in a review of 196 
patients treated for gestational trophoblastic disease over a 5-years period at a major 
specialized center, 7% (14/196) patients had biochemical hyperthyroidism and 4 
had clinical signs and symptoms of hyperthyroidism [31]. Causes of thyrotoxicosis 
in pregnancy are described in Table 1 [27, 28, 32–36].
4.3 Clinical scenarios with Graves’ disease in pregnancy
There are several clinical scenarios related to pregnancy in women with Graves’ 
disease and they will be discussed in detail further.
4.3.1 Preparing for pregnancy in women with known Graves’ disease
Graves’ disease is common in women of reproductive age. Pregnancy should be 
carefully planned because both the characteristic pathogenic antibodies and the 
treatment of GD may be deleterious to the fetus. Also, uncontrolled GD may lead 
to unfavorable outcomes of pregnancy such as miscarriage, gestational hyperten-
sion, preeclampsia, preterm birth, fetal growth restriction, fetal intrauterine 
death, fetal and neonatal goiter, neonatal abnormal thyroid function with potential 
life-long disability for the infant. Contraception is strongly advised in women 
with newly diagnosed GD or in those with uncontrolled GD until euthyroidism 
is reached by treatment. Many patients will first be prescribed ATDs, however 
options of ablative therapy with I131 or surgery (total thyroidectomy) are also 
considered. These options should be discussed with women with GD in relation to 
how they may interfere with a potential pregnancy. Benefits and risks of options 
used for management of GD in women of reproductive age desiring a pregnancy 
are given in Table 2 [4].
Gestational transient thyrotoxicosis









Causes of thyrotoxicosis in pregnancy and postpartum [27, 28, 32–36].
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Antithyroid drugs, thionamides propylthiouracil (PTU), carbimazol and 
methimazole (MMI) have been the traditional mode of treating GD. These drugs 
inhibit the enzyme thyroperoxidase which facilitates the addition of iodine to 
tyrosine in the production of thyroglobulin (Figure 1), an essential step in the 
formation of thyroid hormones. ATDs have their advantages, however, when it 
comes to preparing for pregnancy, counseling on the continuation of treatment and 
on what drugs should be preferred is of great use. ATDs can have adverse effects to 
the mother, but during pregnancy, they can cross the placenta and affect the fetus. 
Use of ATDs in the first trimester of pregnancy has been linked with congenital 
malformations. Later usage may lead to fetal/neonatal hypothyroidism and goiter. 
Carbimazol and methimazole administration during the first trimester and espe-
cially between 6 to 10 weeks has been associated in epidemiological and case-report 
studies with a pattern of anomalies (carbimazole/methimazole embryopathy) 
characterized by dysmorphic facies, choanal atresia, aplasia cutis congenita and 
other skin defects, heart and gastrointestinal abnormalities and abdominal wall 
defects [37]. Prudently, many authorities recommend for pregnant women with 
GD on ATDs, that PTU should be used in the first trimester and MMI thereafter. 
While PTU has a very small risk of maternal liver toxicity, it could be preferred in 
the first trimester, however, switching from one ATD to another at the beginning 
of pregnancy is not an easy process and it may lead to worsening in control of the 
thyroid function which in itself may increase the chance of congenital anomalies 
[37]. Recent reports show that PTU also is not devoid of the risk of congenital 
anomalies. In a Danish study, 2–3% of children exposed to PTU presented facial 
anomalies, necks cysts and urinary tract abnormalities, often requiring surgery in 
later life [38].
Women with GD treated with I131 before at least six months prior to conception 
who are in an euthyroid state had similar outcomes of their pregnancies as healthy 
controls in a retrospective study [39]. Obviously, I131 is contraindicated in preg-
nancy and women undertaking this treatment should prove a negative pregnancy 
test 48 hours prior to it [4].
Total thyroidectomy is the definitive treatment for GD but it can lead to surgical 
complications such as recurrent laryngeal nerve paralysis and hypoparathyroidism. 
Approach Benefits Risks
ATDs Euthyroidism in 1–2 months
Gradual decrease of TRAb
Easy to take, inexpensive
Easy to discontinue or modify
Mild adverse effects: 5%, Severe adverse 
effects: 0.2%
Birth defects (see below)
Relapse after discontinuation: 50%–70%
Ablative therapy (I131) Oral administration
Reduction in goiter size
Relapse rare
Repeat therapy at times
Increase in TRAb for months to years – risk 
for the fetus
Conception delayed for at least 6 months
Worsening of orbitopathy
Lifelong dependence of substitution with 
exogenous levothyroxine
Total thyroidectomy Definitive treatment
Autoimmunity gradually 
resolves
Removal of the goiter
Surgical site complications: 5%
Chronic hypoparathyroidism
Permanent neck scar
Life-long dependence of substitution with 
exogenous levothyroxine
Table 2. 
Benefits and risks of the options for management of GD in women desiring a pregnancy. Adapted and 
modified from [4]; TRAb – TSH receptor antibodies.
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Hypoparathyroidism is the most common complication after total thyroidectomy 
and is usually underrecognized. In a recent retrospective study of patients undergo-
ing total thyroidectomy for benign thyroid conditions, the incidence of transient 
hypoparathyroidism was 43.3% and permanent was 13.4%. In patients with GD 
chronic hypoparathyroidism developed in 27.3% [40]. Entering pregnancy with 
hypoparathyroidism has its own potential risks for both mother and the fetus [41].
A preconceptional visit should ideally be planned for women with known GD 
of reproductive age that are considering pregnancy. This consultation should be 
given by a team of physicians that includes an endocrinologist and a maternal-
fetal medicine specialist/obstetrician with experience in dealing with GD during 
pregnancy. Women with GD seeking pregnancy should be euthyroid – exhibit 
normal levels of thyroid hormones for at least 1–2 months successively. It may 
be sensible that in patients who underwent thyroidectomy but especially in 
those previously treated with I131 ablative therapy, TRAb titers be assessed at 
the preconceptional visit, since the level of these antibodies could interfere with 
fetal thyroid development in the second half of pregnancy and they can remain 
increased many months even years. Pregnancy could be postponed if the levels are 
very high. For those with a total thyroidectomy, parathyroid function should be 
checked if not assessed before. For women with GD, other autoimmune condi-
tions should be looked for and a thorough clinical exam complemented in specific 
cases with targeted tests should be prescribed. A recent systematic review and 
meta-analysis found overt polyautoimmunity in 14% of patients with autoim-
mune thyroid disease. Most common autoimmune conditions associated with GD 
were type 1 diabetes mellitus and autoimmune gastritis, but rheumatological, 
dermatological and neurological autoimmune disorders could also be found in GD 
affected patients [42]. Folic acid is usually recommended to these women in the 
preparation of pregnancy.
4.3.2 Pregnancy in women with Graves’ disease on anti-thyroid drugs
For many women with Graves’ disease ATDs are a good choice of treatment 
gradually inducing remission of autoimmunity. Drugs can be stopped after 
1–2 years of trail, and even though, hyperthyroidism will eventually develop 
in almost 50% of these patients, reactivation of TRAb positivity is not usually 
expected. In a prospective study on 218 patients with GD treated for 12 months with 
ATDs, only 5% of those that were TRAb-negative with treatment became hyper-
thyroid within 8 weeks after stopping the medication [43]. It has therefore been 
suggested that, under good clinical judgment, in women with GD on ATDs that 
become pregnant and that are considered in remission, drugs could be stopped at 
least during the first trimester of pregnancy, especially between weeks 6 to 10, the 
major teratogenic period [4]. This approach is very different from what is recom-
mended for other autoimmune conditions in early pregnancy where discontinu-
ation of the chronic medication is strongly discouraged. Clinical assessment and 
thyroid function tests are recommended frequently in these patients and if relapse 
is diagnosed and ATD therapy is required, PTU is the preferred drug during the 
first trimester. The risk of rapid relapse of hyperthyroidism after stopping ATDs 
during early pregnancy is higher in women that were treated less then 6 months, in 
those that required more then 5 mg MMI per day to remain euthyroid, in those with 
suppressed or low levels of TSH, in those with large goiters, with orbitopathy and 
those with high levels of TRAbs [44].
In women where ATDs can not be discontinued during pregnancy, MMI is 
usually changed with PTU for the first trimester and reintroduced thereafter. Some 
women will have a worsening of their symptoms with GD in the first trimester and 
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improvement later in pregnancy. Many pregnant women will not require ATDs 
by the third trimester as autoimmunity subsides characteristically in pregnancy. 
Normal THS levels and disappearance of maternal TRAb guide the decision to stop 
ATDs. If this is not done, there is a risk of overtreatment that can lead to hypothy-
roidism in the fetus (see below).
4.3.3 When Graves’ disease is first diagnosed in pregnancy
Uncontrolled maternal hyperthyroidism is associated with adverse maternal, 
fetal and neonatal outcomes [4]. When GD is first diagnosed during pregnancy, 
thionamides are the mainstay of treatment and they should be prescribed to achieve 
an euthyroid state. Beta-adrenergic blockers, which are generally considered 
safe in pregnancy, are also prescribed to control the hypermetabolic state until 
patients become euthyroid on ATDs. I131 is contraindicated in pregnancy and 
thyroidectomy, if required should ideally be performed in the second trimester. 
Thyroidectomy is considered for those women that have contraindications to ATDs, 
are not compliant with drug therapy, and in women where euthyroidism is not 
achieved despite large doses of ATDs. Preparation for surgery with beta-blockers 
and a short course of potassium iodide solution (50–100 mg/day) is permitted 
during pregnancy [4]. TRAb levels decrease slowly after surgery, therefore, con-
tinuation of monitoring should be in place for the remainder of pregnancy, since 
these antibodies can cross the placenta when in high titers (> 3 times the upper 
reference for the assay) and render the fetus hyperthyroid despite euthyroid-
ism in the mother. Initial doses of ATDs for GD diagnosed in pregnancy depend 
on the severity of the symptoms and the degree of hyperthyroxinemia. During 
pregnancy MMI is prescribed at doses between 5–30 mg/d, typically in an average 
patient about 10–20 mg; CMZ at 10–40 mg/d and PTU at 100–600 mg/d (typically 
the average dose for PTU in an average patient is 200–400 mg/d). The beneficial 
effects of the drugs are seen gradually over weeks as the reservoir of hormones 
stored in the thyroid gland is consumed. The risk of maternal side effects from 
ATDs is not increased during pregnancy and is similar with one would expect in the 
non-pregnant state. Allergic skin reactions are the most common side effects while 
severe agranulocytosis and liver failure are rarely expected. Because of its potential 
risk of liver hepatotoxicity and liver transplant, some authorities recommend that 
the use of PTU should be limited to the first trimester of pregnancy and considered 
for use thereafter for those with MMI allergy and for those in thyroid storm [4]. 
The greatest concern however, with ATDs use in pregnancy remains their potential 
teratogenic effect and their risk of inducing fetal and neonatal hypothyroidism 
by crossing the placenta. Beta-blockers are considered safe in pregnancy even in 
the first trimester [45]. Usual doses for pregnancy are 10 to 40 mg of propranolol 
every 6 to 8 hours for several weeks. There is a concern related to fetal growth, fetal 
bradycardia and neonatal hypoglycemia with long term use of some beta-blockers 
[46], however propranolol and metoprolol have a more favorable safety profile then 
other beta-blockers during pregnancy [47].
Thyroid function tests could be carried out every 2 to 4 weeks in these patients at 
the beginng of the ATDs course and every 5 to 6 weeks after reaching and euthyroid 
state. When specific population lab values for pregnancy by trimester are not avail-
able, it is recommended to use the reference ranges for nonpregnant patients [4]. [See 
Thyroid function tests in pregnancy above]. The aim of GD treatment is to maintain 
maternal TT4/FT4 values at or just above the pregnancy specific upper limit of normal 
on the lowest effective dose of ATDs, to avoid potential harm to the fetus. Worthy of 
mentioning, ATDs are considered more potent in the fetus then in the mother, hence, 
in a well controlled mother, we could expect hypothyroidism in the fetus.
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4.4 Fetal and neonatal consequences
Fetal and neonatal outcomes of GD are related to the control of the maternal 
hyperthyroid state, the presence or absence of TRAbs and the effect of ATDs. 
Uncontrolled maternal thyrotoxicosis can negatively influence how pregnancy 
progresses. TRAbs, when in high levels can cross the placenta and lead to fetal 
hyperthyroidism and goiter and ATDs, by also crossing the placenta, can lead to 
fetal hypothyroidism and goiter. When assessing a fetus in a mother with GD, a 
maternal-fetal specialist checks with the use of ultrasound the fetal neck in both 
gray-scale and color doppler, looking for signs of fetal goiter. Assessment of fetal 
growth, Doppler studies for assessment of fetal oxygenation, bones, heart rate, 
amniotic fluid volume are also performed. The exact incidence of fetal goiter is not 
known but it may be up to 1 in 5,000 births, usually, but not exclusively, in associa-
tion with maternal Graves’ disease [48]. It has been estimated form different studies 
that the incidence of fetal goiter with either hypo- or hyperthyroidism in mothers 
with treated or untreated Graves’ disease is about 10% [49–53]. Fetal hypothyroid-
ism is found more frequently than fetal hyperthyroidism in mothers with GD 
because of the inadequate use of ATDs [50, 51]. Fetal goiter can be diagnosed prena-
tally by ultrasound with the demonstration of an anterior cervical echogenic mass 
of variable size. (Figure 2) Large fetal goiters may lead to obstruction of fetal swal-
lowing with consequent polyhydramnios and an increased risk of preterm birth; the 
neck may be hyperextended. As with other causes of obstructive polyhydramnios 
(duodenal stenosis, esophageal atresia) this becomes evident usually after 24 weeks’ 
gestation. With fetal goiter there may also be a higher risk of birth dystocia because 
of the inadequate head flexion during labor and increased incidence of neonatal 
breathing problems and difficulties in intubation. Fetal goiter harbors thyroid 
dysfunction. Ultrasound is not a reliable tool to distinguish between fetal hyper- 
and hypothyroidism. In some cases of fetal hyperthyroidism there can be associated 
intrauterine growth restriction with accelerated bone maturation, tachycardia, 
intrauterine death by cardiac failure or thyrotoxicosis and craniosynostosis [54, 55]. 
In severe fetal hypothyroidism there can be a delay in bone maturation [56] and 
there may be impaired growth and bradycardia. There are usually no other associ-
ated structural anomalies and the incidence of chromosomal or genetic anomalies is 
not increased in fetal goiters in maternal Graves’ disease. In terms of management, 
in most cases of fetal goiter, assessment of the maternal condition can help decide 
whether the cause is fetal hypothyroidism or hyperthyroidism. In uncertain cases, 
Figure 2. 
Ultrasound imaging of a fetal thyroid goiter (A in gray scale, B with color doppler). Courtesy of the Fetal 
Medicine Foundation, reproduced with permission.
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cordocentesis and measurement of fetal blood thyroid hormones and TSH can help 
distinguish between hypothyroidism, with low thyroid hormones and high TSH, 
due to ATDs and hyperthyroidism, with high thyroid hormones and low TSH, due 
to TRAbs [49, 57]. Normal ranges for the thyroid hormones level in the fetal blood 
have been previously reported [58, 59].
In fetal hypothyroid goiter the first-line of treatment is to reduce or even discon-
tinue maternal ATD medication aiming to maintain maternal blood thyroxine in the 
upper level of the gestational age-specific normal range. As noted before, GD, simi-
lar to other autoimmune conditions, improves during pregnancy and consequently 
requires less medication. The second-line of treatment is intra-amniotic injection 
of levothyroxine (100 μg/kg) every 1–2 weeks until delivery at term [49, 60]. The 
goiter usually decreases in size within a few days to weeks after the first course of 
treatment. Subsequent injections are given depending on sonographic evidence of 
re-enlargement of the gland or serial measurements of levels of thyroid hormones 
in amniotic fluid or fetal blood [49, 61, 62].
In fetal hyperthyroid goiter the treatment is administration of ATDs to the 
mother [63]. Occasionally, the mother should also be given levothyroxine, as the 
dose of ATDs can be appropriate for the fetus but could lead to hypothyroidism in 
the mother (one of the few occasions block and replace therapy is used) [4]. The 
fetal goiter usually decreases in size after initiation of the treatment, but if this does 
not occur measurement of levels of thyroid hormones in fetal blood [24] may be 
needed and the dose of ATDs adjusted. Follow-up should be arranged depending 
on the clinical context, but generally at every 2–4 weeks to monitor fetal growth, 
size of the tumor, fetal heart rate, amniotic fluid volume and cervical length (for 
the prediction of risk of preterm birth). Delivery in the case of fetal goiter should 
take place in a hospital with neonatal intensive care capacities and pediatric surgery 
facilities, ideally around 38 weeks. With large goiters, where there is hyperexten-
sion of the neck, cesarean section is preferred for delivery. An EXIT (ex utero 
intrapartum treatment) procedure may be required to access and stabilize neonatal 
breathing while maintaining placental flow through the umbilical cord from the 
mother [24]. Adequately treated fetal thyroid goiters generally have good prognosis. 
However, fetal hyperthyroidism may lead to neonatal thyrotoxicosis [64] and, to 
long term intellectual impairment [65] while fetal hypothyroidism may result in 
long term abnormal psychomotor development [66].
Neonatal thyroid function abnormalities are frequent in newborns of moth-
ers with GD. In a recent study in 32 newborns from mothers with GD, 3 cases had 
hypothyroidism and 2 had hyperthyroidism despite not showing a goiter. These 
affected babies all had higher levels of TRAbs in their cord blood at delivery and in 
the follow-up tests [67]. Newborns of mothers with GD can present with hyper-
thyroidism but also with central or primary hypothyroidism. There are no clear 
guidelines as to how these neonates should be followed, but most authorities do 
recommend testing for TRAbs in the cord blood/blood with subsequent discharge 
of negative testing newborns. FT4 and TSH can be performed at 3 to 5 days of life 
and repeated at 10 to 14 days. For hyperthyroid newborns MMI and beta-blockers 
can be used [68]. Maternal TRAbs passed to the newborn will be cleared from the 
neonates’ serum within weeks to months as in the case of other maternal autoim-
mune conditions [48].
4.5 The postpartum in women with GD
Worsening of GD, relapse or need for increased medication do occur after 
delivery even in mothers that were previously under remission [69, 70] and 
women should be counseled and informed about this. Pregnant women with 
Graves’ Disease
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positive TRAbs in early pregnancy are at high-risk of developing postpartum GD. 
Postpartum GD usually occurs after 3 months from delivery and this helps in dif-
ferentiating it from other forms of thyrotoxicosis specific to this period that tend 
to develop earlier. Women with known GD before or during pregnancy should be 
regularly checked with thyroid function tests in the postpartum. Treatment options 
for postpartum GD are the same as for any GD patient. ATDs are an initial good 
choice since in many instances GD postpartum can be transient and mothers can 
continue breastfeeding on them. Both MMI (up to maximal recommended dose of 
20 mg/d) and PTU (up to maximal dose of 450 mg/d) can be safely administered 
in breastfeeding mothers [4]. Monitoring the infants for appropriate growth and 
development routinely is advised [4]. It may be necessary to check the infants’ thy-
roid function when antithyroid drugs are administered at higher doses. Medication 
should be taken just after breastfeeding, which should provide a 3 to 4 hours lactat-
ing free interval [71]. Considering the possibility of side effects of severe hepatic 
injury of PTU in mothers and infants [72], and high incidence of general side 
effects with PTU [73], MMI is the preferred drug in the treatment of breastfeeding 
women. The use of I131 is strictly contraindicated during lactation. If circumstances 
require it I123, when available can be used in lactating women. The half-life of 123I 
is 13 hours so breast milk should be pumped and discarded for 3–4 days until the 
radioactive iodine has cleared from the body [74]. Similarly, Tc-99 m pertechnetate 
administration requires breast milk to be pumped and discarded during the day of 
testing [4].
5. Conclusions
Graves’ disease is frequent in women of reproductive age and in pregnancy. It 
can lead to maternal, fetal and neonatal complications with potential long-term 
sequels. For those with known GD before pregnancy a preconception plan should 
be made to ensure optimal timing for pregnancy when GD is well under control. 
Management options for GD and their implications to pregnancy should be dis-
cussed. TRAbs are the pathogenic hallmark of GD and they can cause harm to the 
fetus and the neonate by crossing the placenta. Antithyroid drugs are traditionally 
used to treat GD, however in pregnancy they can be teratogenic and they can induce 
fetal and neonatal hypothyroidism by placental passage. Fetal ultrasound during 
pregnancy is helpful for fetal assessment and for diagnosing fetal goiter. The type 
of fetal thyroid disfunction when goiter is associated can be usually deduced by 
assessing the maternal state. Fetal treatment is in most cases achieved by treating 
the mother – increasing or decreasing ATDs. Neonatal assessment in newborns of 
mothers with known GD is recommended. Maternal GD, like other autoimmune 
conditions can flare in the postpartum, therefore, the mother should also be under 
supervision. Breastfeeding is allowed in women on regular doses of ATDs.
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